Galderma Group AG
GALD
Rank in Stocks
#459
Galderma Group AG operates as a dermatology company worldwide. The company... Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Share Price
$224.81
Market Cap
$52.42B
Change (1 day)
6.31%
Change (1 year)
31.28%
Country
CH
Trade Galderma Group AG (GALD)
Category
Healthcare
Revenue for Galderma Group AG (GALD)
Revenue in Oct 2026 TTM: 0
According to Galderma Group AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Galderma Group AG from 2021 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $5.24B | 7.20% |
| 2024 | $4.89B | 14.04% |
| 2023 | $4.29B | 10.40% |
| 2022 | $3.88B | 13.67% |
| 2021 | $3.42B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| $29.24B | - |
JP
|
|
| $6.61B | - |
IN
|
|
| $4.69B | - |
CN
|
